Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.24 +2.5%	$1.37	$1.05 ▼ $10.16	$38.88M	1.55	255,109 shs	283,795 shs
ELYM Eliem Therapeutics	$1.23 +2.5%	$1.26	$2.35 ▼ $11.55	$36.60M	-0.39	486,688 shs	283,275 shs
KPTI Karyopharm Therapeutics	$4.44 +1.8%	$5.11	$3.51 ▼ $17.40	$38.36M	0.23	81,762 shs	33,949 shs
TRAW Traws Pharma	$1.65 -0.6%	$1.55	$0.97 ▼ $19.44	$9.18M	1.48	444,389 shs	61,835 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	+2.48%	-2.36%	+5.08%	-75.88%	-81.30%
ELYM Eliem Therapeutics	-5.51%	-12.41%	-6.98%	-11.11%	-83.67%
KPTI Karyopharm Therapeutics	+1.83%	+1.14%	-13.45%	-27.69%	-68.17%
TRAW Traws Pharma	-0.60%	-10.33%	+23.13%	-42.71%	+164,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRV Acrivon Therapeutics	4.2461 of 5 stars	4.5	5.0	0.0	0.0	2.7	3.3	0.6
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	3.7476 of 5 stars	3.5	1.0	0.0	4.6	0.6	2.5	0.6
TRAW Traws Pharma	0.2362 of 5 stars	0.0	3.0	0.0	0.0	1.1	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	3.00	Buy	$17.71	1,328.57% Upside
ELYM Eliem Therapeutics	0.00	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	3.00	Buy	$43.20	872.97% Upside
TRAW Traws Pharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TRAW, ELYM, ACRV, and KPTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	ACRV Acrivon Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/15/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00
5/5/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
5/4/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/26/2025	ACRV Acrivon Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/26/2025	ACRV Acrivon Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $19.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$5.68 per share	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	$3.90 per share	N/A
KPTI Karyopharm Therapeutics	$145.24M	0.26	N/A	N/A	($22.10) per share	-0.20
TRAW Traws Pharma	$230K	39.89	N/A	N/A	($8.66) per share	-0.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$80.56M	-$2.22	N/A	N/A	N/A	N/A	-44.66%	-40.94%	8/12/2025 (Estimated)
ELYM Eliem Therapeutics	-$35.12M	-$0.53	N/A	∞	N/A	N/A	-47.03%	-45.97%	N/A
KPTI Karyopharm Therapeutics	-$76.42M	-$13.26	N/A	N/A	N/A	-43.99%	N/A	-35.95%	8/5/2025 (Estimated)
TRAW Traws Pharma	-$166.52M	-$32.81	N/A	N/A	N/A	-15,245.81%	N/A	-193.21%	8/13/2025 (Estimated)

Latest TRAW, ELYM, ACRV, and KPTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	TRAW Traws Pharma	-$8.04	$2.09	+$10.13	$2.09	$0.06 million	$0.06 million
5/13/2025	Q1 2025	ACRV Acrivon Therapeutics	-$0.57	-$0.51	+$0.06	-$0.51	N/A	N/A
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
3/31/2025	Q4 2024 & Study Update	TRAW Traws Pharma	-$7.00	$95.66	+$102.66	$95.66	$0.06 million	$0.06 million
3/27/2025	Q4 2024	ACRV Acrivon Therapeutics	-$0.69	-$0.60	+$0.09	-$0.60	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
TRAW Traws Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	11.17	11.17
ELYM Eliem Therapeutics	N/A	60.41	60.41
KPTI Karyopharm Therapeutics	N/A	1.33	1.28
TRAW Traws Pharma	N/A	1.81	1.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
ELYM Eliem Therapeutics	69.76%
KPTI Karyopharm Therapeutics	66.44%
TRAW Traws Pharma	7.95%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	11.90%
ELYM Eliem Therapeutics	4.70%
KPTI Karyopharm Therapeutics	2.98%
TRAW Traws Pharma	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	31.35 million	27.62 million	Not Optionable
ELYM Eliem Therapeutics	9	29.75 million	28.35 million	Not Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	8.38 million	Optionable
TRAW Traws Pharma	17	5.56 million	4.81 million	Optionable

TRAW, ELYM, ACRV, and KPTI Headlines

Recent News About These Companies

Traws Pharma Announces Promising Clinical Data for Rigosertib in Rare Cancer

June 5, 2025 | msn.com

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

June 3, 2025 | globenewswire.com

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

May 27, 2025 | globenewswire.com

Traws Pharma Unveils New Strategic Antiviral Focus

May 19, 2025 | tipranks.com

Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments

May 18, 2025 | msn.com

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

May 15, 2025 | globenewswire.com

Traws Pharma Appoints New Chairman Amid Leadership Changes

April 18, 2025 | tipranks.com

The Escalator: HHS, Spectrum Science, Alvotech and more

April 3, 2025 | mmm-online.com

Traws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID Programs

April 2, 2025 | msn.com

Traws Pharma reports FY24 EPS ($35.21)

April 1, 2025 | markets.businessinsider.com

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

April 1, 2025 | seekingalpha.com

Traws Pharma, Inc.: Traws Pharma Reports Full Year 2024 Results and Business Highlights

March 31, 2025 | finanznachrichten.de

Traws Pharma Reports Full Year 2024 Results and Business Highlights

March 31, 2025 | markets.businessinsider.com

Traws Pharma Announces CEO Transition as Werner Cautreels Retires

March 30, 2025 | msn.com

Traws Pharma, Inc.: Traws Pharma Announces Management Updates

March 29, 2025 | finanznachrichten.de

Traws Pharma: Werner Cautreels to Retire as CEO, While Continuing as a Bd Member >TRAW

March 29, 2025 | marketwatch.com

Traws Pharma: Werner Cautreels to Retire as CEO, While Continuing as a Bd Member >TRAW

March 29, 2025 | marketwatch.com

Traws Pharma Announces Virtual Investor Event to Showcase Innovative Treatments for Bird Flu and COVID-19

March 29, 2025 | msn.com

Traws Pharma CEO Werner Cautreels retires, Iain Dukes named interim CEO

March 29, 2025 | markets.businessinsider.com

Traws Pharma Announces Management Updates

March 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAW, ELYM, ACRV, and KPTI Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.24 +0.03 (+2.48%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.26 +0.02 (+1.94%)

As of 06/18/2025 07:28 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Eliem Therapeutics NASDAQ:ELYM

$1.23 +0.03 (+2.50%)

As of 06/18/2025

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Karyopharm Therapeutics NASDAQ:KPTI

$4.44 +0.08 (+1.83%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$4.37 -0.07 (-1.67%)

As of 06/18/2025 07:53 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Traws Pharma NASDAQ:TRAW

$1.65 -0.01 (-0.60%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.64 0.00 (-0.30%)

As of 06/18/2025 07:53 PM Eastern

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time